| abstract |
The present invention is based in part on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the present invention would be beneficial to modulate PD-1, PD-L1, and / or PD-L2 activity using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein. It relates to compositions and methods for the diagnosis, prognosis observation and treatment of conditions (eg, persistent infectious disease, autoimmune disease, asthma, transplant rejection, inflammatory disease and tumor). |